With rising competition from companies like Roche and others, is continuing to downsize R&D investment truly the right strategy? We need an entrepreneurial CEO—one who is bold and visionary—to clearly articulate our genuine growth plan to investors. Instead of focusing solely on margin calculations through cuts, we should invest more now to develop groundbreaking products and outpace our rivals. I believe Wall Street would prefer a company with strong growth potential over one with lackluster expansion but improved margins from relentless cost reductions. The current share price speaks volumes: investors are not buying into Illumina’s new strategy.
2 replies (most recent on top)
Their strategies are working well especially on moving activities out of US. Quite a bit has moved to APAC operation leading to the build up of locally recruited management staff to their already bloated management level.
So be encouraged to ask for transfer to APAC operation to ensure job stability and advencement. Go take a look at the vacancies opening and give it a bang.
Good luck and see you soon at APAC operation. .
The strategy is working. Here's how: by degrading the wealth of the employees, they're going to be docile and desperate to keep their jobs. Meanwhile, keep moving more functions outside the US to maximize the revenue and keep the shareholders happy. It's not smart, but effective on its main goal: Jacob and the other sociopaths will line their pockets, while blaming the employees for the "lack of productivity and accountability". Lots of psychological projection from the CEO.